

REMARKS/ARGUMENTS

Support for the Amendment

The list of dosage amounts in milligrams in claim 29 is taken from Table I at page 13 of the specification. No new matter is presented. This amendment, including the clarifying wording preceding the table in each of these claims, is made in response to the examiner's suggestion by telephone on September 20, 2007.

Claim Rejections - 35 U.S.C. § 103(a)

The rejection of claims 29 and 30 as unpatentable for obviousness over Richardson et al. US 6,207,190, Murad US 5,804,594, and Fahim US 4,937,234 is respectfully traversed and is now understood to be moot, the examiner having since acknowledged the acceptance of Applicants' Terminal Disclaimer dated June 11, 2007 removing the Richardson et al. patent from consideration as prior art.

All objections and rejections now having been addressed and obviated, Applicants believe all claims now pending in this Application are in condition for allowance, and reconsideration of the application is therefore respectfully requested. Should any matters remain that can be resolved by a conference with Applicants' attorney, the examiner is encouraged to telephone the undersigned at 415-576-0200.

Respectfully submitted,



M. Henry Heines
Reg. No. 28,219

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200; Fax: 415-576-0300
MHH:mhh
61161964 v1